Dapagliflozin lowers plasma glucose concentration and improves β-cell function - Wikidata - awgldk - TriplyDB

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

http://www.wikidata.org/entity/Q35578244

about

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Practical combination therapy based on pathophysiology of type 2 diabetes Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in db/db Mice.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Dapagliflozin for the treatment of type 1 diabetes mellitus.Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.SGLT2 inhibitors: are they safe?Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

P2860

Q26775823-47F6EA18-60D3-4340-BC6A-0456F9538DF8 Q26782225-2EF53AA0-87CD-43AE-BCEE-D669C893832F Q28072765-A037C62E-1869-42B9-B4CC-74D124594EB8 Q28076530-69437EBC-3638-451D-8E52-733F2B6DF1CB Q28080114-48F3D32A-6FE4-4A9E-AF77-033FB1EAE96B Q33763305-B75DB87D-32F1-4468-928A-D120AAF55184 Q36341246-A313D460-5CE7-4930-89B0-5FD926C4973F Q36345951-74BC060B-4A2C-4BFF-AAFE-C3E3634644E8 Q37354187-68856AF7-97AF-4141-82F1-6E69FA65589C Q38524435-FE8ADBB6-9AB6-4967-B016-084E18EB3748 Q38592327-B6AE8E98-A484-4FFB-B8EA-095A7D578C53 Q38619164-0F11B9D0-5304-4F52-8575-48E8139D323F Q38751451-6752DD8F-0918-49E5-BDAA-374586657336 Q38783203-6D5BF641-7414-4EB3-9B97-CA54CFCE85CA Q38784851-2CD5FE9E-E240-4FAF-8261-32FD7538D67B Q38796262-7217DC2E-4C45-423B-AEA1-A863454322BB Q39000587-40FE9D4E-30C0-4921-ADE3-23FEA55ECA40 Q39255188-DD0F412F-FBCF-44B4-A158-F220007550ED Q39255963-B3B8116D-5045-4F14-BAB0-6E063EB321A1 Q39354776-826EF628-62AA-4887-89CB-DA8504428A42 Q39393777-B3E8C673-A5D9-4B74-BF35-018C830575D3 Q39409421-CD6EAC04-EBD5-4D0F-AB58-1AAB9CD4B273 Q39821664-EB367867-F7D0-4D4E-BE61-29CB1DEB09BC Q40405896-9A3F36DC-2716-491A-BC4C-9CB01351AD26 Q42718201-E3B3152C-EA6A-415C-BC5C-5A0EA9155167 Q47115045-5C1090DB-59D5-4AB3-8FCC-8F51F6C1A32D Q47642298-75EAD334-3443-4D3C-8E0E-D2AF637E0870 Q47849041-9AA49D64-BECF-4E5A-9F14-944423FD9E9B Q48185851-EE887932-0759-4685-8E90-9A7E533BCFEF Q48304621-F81ED4D3-D25B-4E78-813D-9C3EF7B6A83F Q51276351-A2EB4BCC-8118-4F50-9F13-C5EFEDEA4A3A

P2860

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

http://www.wikidata.org/entity/Q35578244

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@ast

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@en

type

label

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@ast

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@en

prefLabel

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@ast

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@en

P1433

Q35578244-EBF5488B-1444-4D1F-B2B7-94BE8FC1B133

P1476

Q35578244-5766C631-D8A9-4BB4-93B2-1817EF03290F

P2093

Q35578244-3E927C59-8699-4CD9-B520-841F9665EA08

Q35578244-4E97DC1C-D32F-4265-8D4C-5B496FDC5885

Q35578244-4F983305-D5CE-430B-B083-CAA373BE6738

Q35578244-5E464D6D-19DE-493A-AF4A-9CE963EBCB11

Q35578244-71B43A0B-57C6-4AA7-8C37-4A2762F8F014

Q35578244-EAD0EF43-F456-4050-AC47-193D3DC80B59

Q35578244-EDB74BF4-8BB4-470B-B129-57D507F20808

Q35578244-FF3CA6FF-E224-48DF-B6A9-7519136DF9D5

P2860

Q35578244-02C145E5-E3DA-4A69-8FF2-C9C4C3E3AE78

Q35578244-0950DD95-852C-487D-856E-58DBCEF78283

Q35578244-0EB00178-B4B7-440A-ADD0-C518D4E79B14

Q35578244-19E5C716-D930-43AC-8BCD-1551FDE3AA5D

Q35578244-1A04C9D6-908E-4CB7-8BDA-8B836C692189

Q35578244-353C5EAA-1115-483A-BF44-69020A907BF2

Q35578244-38DC6510-A09F-44F3-9585-E27D6AE1DD35

Q35578244-3BD0A130-EDF5-4605-9DD1-20B858F03502

Q35578244-3BD17D2E-1CBE-4EE9-9B36-F221144F10A7

Q35578244-43774B0A-7CCA-4AFC-B276-378F8201CE09

P304

Q35578244-E7F81A1E-E864-42A3-B431-DCC5A3B1FABC

P31

Q35578244-82FE246C-6A50-48A5-BD30-63E388B62D76

P356

Q35578244-F68FFCC0-62F7-4724-942C-54A01824296B

P407

Q35578244-C94345C2-2D9F-4499-8D57-2158774B3E42

P433

Q35578244-EFA7879C-D85C-440F-AD65-642FC523733F

P478

Q35578244-EB5AF63D-83D2-4A04-B72F-4DAFA6A250E8

P50

Q35578244-5243581A-F53E-41FC-A559-4AA88732CF5B

Q35578244-806607BF-9514-4CDE-B701-353EB7D184DA

P577

Q35578244-5CB9DEE6-1A76-4F3B-8483-6E68ACC7808C

P698

Q35578244-F3A3E2D3-7CFE-4232-B2BB-BB7CD881D470

P921

Q35578244-C2EEBB5F-4882-45D8-9A07-C478B306907E

P932

Q35578244-D37658CB-3804-43B1-A77E-45FFE26D1C04

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

@en

P2093

Alberto Chavez-Velazquez

http://www.w3.org/2001/XMLSchema#string

Andrea Mari

http://www.w3.org/2001/XMLSchema#string

Aurora Merovci

http://www.w3.org/2001/XMLSchema#string

Carolina Solis

http://www.w3.org/2001/XMLSchema#string

Devjit Tripathy

http://www.w3.org/2001/XMLSchema#string

Juan Xiong

http://www.w3.org/2001/XMLSchema#string

Muhammad Abdul-Ghani

http://www.w3.org/2001/XMLSchema#string

Scheherezada Urban McCarthy

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy.

Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study.

Chronic pulsatile hyperglycemia reduces insulin secretion and increases accumulation of reactive oxygen species in fetal sheep islets.

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

P304

1927-1932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2014-3472

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Daniele

Ralph A DeFronzo

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25710563

http://www.w3.org/2001/XMLSchema#string

P921

P932

4422889

http://www.w3.org/2001/XMLSchema#string